Some literature sources have also cited it as the CD6 ligand (CD6L). It is expressed on activatedT cells, activatedmonocytes,epithelial cells,fibroblasts,neurons,melanoma cells, and also insweat andsebaceous glands.[citation needed] CD166 protein expression is reported to be upregulated in a cell line deriving from a metastasizing melanoma.[7] CD166 plays an important role in mediating adhesion interactions between thymic epithelial cells and CD6+ cells during intrathymic T cell development.[citation needed]
Recently, CD166 has also been used as a potential cancer stem cell marker.[citation needed]
Skonier JE, Bowen MA, Emswiler J, et al. (1996). "Recognition of diverse proteins by members of the immunoglobulin superfamily: delineation of the receptor binding site in the human CD6 ligand ALCAM".Biochemistry.35 (38):12287–91.doi:10.1021/bi961038k.PMID8823162.
Singer NG, Mitra R, Lialios F, et al. (1998). "CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on gamma-interferon activated keratinocytes".Immunol. Lett.58 (1):9–14.doi:10.1016/S0165-2478(97)02707-7.PMID9436462.
Cortés F, Deschaseaux F, Uchida N, et al. (1999). "HCA, an immunoglobulin-like adhesion molecule present on the earliest human hematopoietic precursor cells, is also expressed by stromal cells in blood-forming tissues".Blood.93 (3):826–37.doi:10.1182/blood.V93.3.826.PMID9920831.
Tomita K, van Bokhoven A, Jansen CF, et al. (2000). "Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin".Biochem. Biophys. Res. Commun.267 (3):870–4.Bibcode:2000BBRC..267..870T.doi:10.1006/bbrc.1999.2040.PMID10673383.
Kristiansen G, Pilarsky C, Wissmann C, et al. (2003). "ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions".Prostate.54 (1):34–43.doi:10.1002/pros.10161.PMID12481253.S2CID22749852.
Zhang H, Li XJ, Martin DB, Aebersold R (2003). "Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry".Nat. Biotechnol.21 (6):660–6.doi:10.1038/nbt827.PMID12754519.S2CID581283.
Verma A, Shukla NK, Deo SV, et al. (2005). "MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma".Oncology.68 (4–6):462–70.doi:10.1159/000086989.PMID16024937.S2CID25355369.
